scholarly journals Structural and Functional Properties of the Capsid Protein of Dengue and Related Flavivirus

2019 ◽  
Vol 20 (16) ◽  
pp. 3870 ◽  
Author(s):  
Faustino ◽  
Martins ◽  
Karguth ◽  
Artilheiro ◽  
Enguita ◽  
...  

Dengue, West Nile and Zika, closely related viruses of the Flaviviridae family, are an increasing global threat, due to the expansion of their mosquito vectors. They present a very similar viral particle with an outer lipid bilayer containing two viral proteins and, within it, the nucleocapsid core. This core is composed by the viral RNA complexed with multiple copies of the capsid protein, a crucial structural protein that mediates not only viral assembly, but also encapsidation, by interacting with host lipid systems. The capsid is a homodimeric protein that contains a disordered N-terminal region, an intermediate flexible fold section and a very stable conserved fold region. Since a better understanding of its structure can give light into its biological activity, here, first, we compared and analyzed relevant mosquito-borne Flavivirus capsid protein sequences and their predicted structures. Then, we studied the alternative conformations enabled by the N-terminal region. Finally, using dengue virus capsid protein as main model, we correlated the protein size, thermal stability and function with its structure/dynamics features. The findings suggest that the capsid protein interaction with host lipid systems leads to minor allosteric changes that may modulate the specific binding of the protein to the viral RNA. Such mechanism can be targeted in future drug development strategies, namely by using improved versions of pep14-23, a dengue virus capsid protein peptide inhibitor, previously developed by us. Such knowledge can yield promising advances against Zika, dengue and closely related Flavivirus.

2013 ◽  
Vol 104 (2) ◽  
pp. 415a
Author(s):  
Filomena A. Carvalho ◽  
Ivo C. Martins ◽  
Fabiana A. Carneiro ◽  
Iranaia Assunção-Miranda ◽  
André F. Faustino ◽  
...  

2017 ◽  
Vol 12 (5) ◽  
pp. 1257-1268 ◽  
Author(s):  
Vera Neves ◽  
Frederico Aires-da-Silva ◽  
Maurício Morais ◽  
Lurdes Gano ◽  
Elisabete Ribeiro ◽  
...  

Author(s):  
Iris Cadima-Couto ◽  
Alexandra Tauzin ◽  
João M. Freire ◽  
Tiago N. Figueira ◽  
Rúben D. M. Silva ◽  
...  

2013 ◽  
Vol 87 (24) ◽  
pp. 13094-13106 ◽  
Author(s):  
C. A. Balinsky ◽  
H. Schmeisser ◽  
S. Ganesan ◽  
K. Singh ◽  
T. C. Pierson ◽  
...  

2009 ◽  
Vol 154 (8) ◽  
pp. 1211-1221 ◽  
Author(s):  
Chunya Puttikhunt ◽  
Prapapun Ong-ajchaowlerd ◽  
Tanapan Prommool ◽  
Sutha Sangiambut ◽  
Janjuree Netsawang ◽  
...  

2009 ◽  
Vol 391 (2) ◽  
pp. 314-326 ◽  
Author(s):  
Guanghui Yi ◽  
Robert C. Vaughan ◽  
Ian Yarbrough ◽  
S. Dharmaiah ◽  
C. Cheng Kao

2009 ◽  
Vol 5 (10) ◽  
pp. e1000632 ◽  
Author(s):  
Marcelo M. Samsa ◽  
Juan A. Mondotte ◽  
Nestor G. Iglesias ◽  
Iranaia Assunção-Miranda ◽  
Giselle Barbosa-Lima ◽  
...  

2020 ◽  
Author(s):  
Debica Mukherjee ◽  
Rupesh Roy ◽  
UPASANA RAY

<p></p><p>In the middle of SARS-CoV-2 pandemic, dengue virus (DENV) is giving a silent warning as the season approaches nearer. There is no specific antiviral against DENV for use in the clinics. Thus, considering these facts we can potentially face both these viruses together increasing the clinical burden. The search for anti-viral drugs against SARS-CoV-2 is in full swing and repurposing of already ‘in-use’ drugs against other diseases or COVID-19 has drawn significant attention. Earlier we had reported few FDA approved anti-viral and anti-microbial drugs that could be tested for binding with SARS-CoV-2 nucleocapsid N terminal domain. We explored the possibility of interactions of the drugs screened for SARS-CoV2 with Dengue virus capsid protein. We report five FDA approved drugs that were seen to be docking onto the SARS-CoV-2 nucleocapsid RNA binding domain, also docking well with DENV capsid protein on the RNA binding site and/or the capsid’s membrane fusion domain. Thus, the present study proposes these five drugs as common antiviral candidates against both SARS-CoV-2 and DENV although the <i>in silico</i> study is subject to further validations.</p><br><p></p>


Sign in / Sign up

Export Citation Format

Share Document